ATAI Life Sciences (NASDAQ: ATAI) shares Q2 2025 results and updates

Rhea-AI Filing Summary

ATAI Life Sciences N.V. filed a current report stating that on August 14, 2025 it issued a press release with its financial results for the quarter ended June 30, 2025 and shared corporate and clinical updates. The press release is furnished as Exhibit 99.1 and is not treated as formally filed for liability purposes or automatically incorporated into other securities filings.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

false000184090400-000000000018409042025-08-142025-08-14

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): August 14, 2025

ATAI LIFE SCIENCES N.V.

(Exact name of registrant as specified in its charter)

The Netherlands	001-40493	Not Applicable
(State or other jurisdiction of incorporation or organization)	(Commission File Number)	(I.R.S. Employer Identification No.)

Prof. J.H. Bavincklaan 7

1183 AT Amstelveen

The Netherlands

(Address of principal executive offices) (Zip Code)

+31 20 793 2536

(Registrant’s telephone number, including area code)

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☒
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common shares, €0.10 par value per share		ATAI		The Nasdaq Stock Market LLC (Nasdaq Global Market)

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

On August 14, 2025, ATAI Life Sciences N.V. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2025 and provided corporate and clinical updates. A copy of the press release is being furnished to the Securities and Exchange Commission as Exhibit 99.1 to this Current Report on Form 8-K (“Form 8-K”).

The information in this Item 2.02 of this Form 8-K (including Exhibit 99.1 attached hereto) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1*		Press Release of ATAI Life Sciences N.V., dated August 14, 2025.
104		Cover Page Interactive Data File (embedded within the inline XBRL document).
*		Furnished herewith

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	ATAI LIFE SCIENCES N.V.
Date:   August 14, 2025	By:	/s/ Srinivas Rao
	Name:	Srinivas Rao
	Title:	Chief Executive Officer

FAQ

What did ATAI (ATAI) disclose in this 8-K filing?

ATAI Life Sciences N.V. disclosed that it issued a press release announcing its financial results for the quarter ended June 30, 2025 and provided corporate and clinical updates.

Which period do the latest ATAI (ATAI) financial results cover?

The financial results announced by ATAI Life Sciences N.V. cover the quarter ended June 30, 2025.

Where can investors find the detailed Q2 2025 results for ATAI (ATAI)?

The detailed results and updates are contained in ATAI Life Sciences N.V.’s press release, which is attached as Exhibit 99.1 to the report.

Does the ATAI (ATAI) press release form part of ATAI’s filed financial statements?

No. ATAI Life Sciences N.V. states that the information in Item 2.02 and Exhibit 99.1 is furnished, not filed, and is not subject to Section 18 liability or automatically incorporated into other filings.

Who signed the ATAI (ATAI) 8-K related to the Q2 2025 results?

The report was signed on behalf of ATAI Life Sciences N.V. by Srinivas Rao, its Chief Executive Officer.

What exhibits are included with ATAI’s (ATAI) 8-K filing dated August 14, 2025?

The report includes Exhibit 99.1, the press release dated August 14, 2025, and Exhibit 104, the cover page interactive data file.